CS259232B1 - Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens - Google Patents
Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens Download PDFInfo
- Publication number
- CS259232B1 CS259232B1 CS861487A CS148786A CS259232B1 CS 259232 B1 CS259232 B1 CS 259232B1 CS 861487 A CS861487 A CS 861487A CS 148786 A CS148786 A CS 148786A CS 259232 B1 CS259232 B1 CS 259232B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- surface antigens
- monoclonal antibody
- acid
- lymphocytes
- producing monoclonal
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 14
- 102000036639 antigens Human genes 0.000 title claims abstract description 14
- 108091007433 antigens Proteins 0.000 title claims abstract description 14
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 11
- 244000144977 poultry Species 0.000 title abstract description 10
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 23
- 101100024330 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSB1 gene Proteins 0.000 abstract description 13
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 210000004989 spleen cell Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 3-indolyl Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229960005508 8-azaguanine Drugs 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- VVNHKANZTYIZTL-UHFFFAOYSA-M 1-hydroxyethyl(trimethyl)azanium;chloride Chemical compound [Cl-].CC(O)[N+](C)(C)C VVNHKANZTYIZTL-UHFFFAOYSA-M 0.000 description 1
- FWBXNMSLCRNZOV-UHFFFAOYSA-N 2-amino-3-imidazol-1-ylpropanoic acid Chemical compound OC(=O)C(N)CN1C=CN=C1 FWBXNMSLCRNZOV-UHFFFAOYSA-N 0.000 description 1
- HOZBSSWDEKVXNO-DKWTVANSSA-N 2-aminobutanedioic acid;(2s)-2-aminobutanedioic acid Chemical compound OC(=O)C(N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-DKWTVANSSA-N 0.000 description 1
- UJKDYMOBUGTJLZ-DFWYDOINSA-N 2-aminopentanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)C(N)CCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O UJKDYMOBUGTJLZ-DFWYDOINSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- YDHIMEXEGOCNHU-UHFFFAOYSA-N 2-pyridin-3-ylacetamide Chemical compound NC(=O)CC1=CC=CN=C1 YDHIMEXEGOCNHU-UHFFFAOYSA-N 0.000 description 1
- ROQLQGQHEMKBKA-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1.NC1=CC=C(C(O)=O)C=C1 ROQLQGQHEMKBKA-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- PYBJXGMADOFKRB-YDALLXLXSA-N C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1)(=O)O.NC1=NC2=NC=C(N=C2C(=N1)O)CNC1=CC=C(C(=O)O)C=C1 Chemical compound C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2=CN=C3N=C(N)NC(=O)C3=N2)C=C1)(=O)O.NC1=NC2=NC=C(N=C2C(=N1)O)CNC1=CC=C(C(=O)O)C=C1 PYBJXGMADOFKRB-YDALLXLXSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ALUBSZXSNSPDQV-WDSKDSINSA-N Gln-Cys-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ALUBSZXSNSPDQV-WDSKDSINSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Očelom riešenia je příprava izotypovo a idiotypovo homogénnej protilátky o vysokej čistotě. Uvedeného účelu sa dosiahne použitím myšieho lymfocytárneho hybridómu MSB-NTP-3 produkujúceho monoklonálnu protilátku rozpoznávejúcu povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych slezinových buniek hydiny. Myší lymfocytámy hybridóm má použitie vo veterinárněj medicíně.The solution is to prepare isotype and an idiotypic homogeneous antibody of high purity. This purpose is achieved using a mouse lymphocyte hybridoma MSB-NTP-3 producing monoclonal antibody recognizing surface antigens lymphoblastoid cell line labeled MSB1 and normal spleen poultry cells. Hybridoma mouse lymphocytes has use in veterinary medicine.
Description
Vynález sa týká myšieho lymfocytárneho hybrldomu produkujúceho monoklonálnu protilátku rozpoznávajúcu povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych slezinových buniek hydiny.The invention relates to a murine lymphocyte hybridoma producing a monoclonal antibody recognizing the surface antigens of the lymphoblastoid cell line designated MSB1 and normal spleen cells of poultry.
Doposial sa protilátky proti lymfoblastoidnej bunkovej linii MSB1, ktorá nesie na svojom povrchu diagnostický antigén MATSA připravovali tak, že sa pokusným zvieratám /králik, ovca/ aplikovali živé MSB1 buňky. Vzhládom na to, že nestačí jedna dávka buniek pre vyvolanie dostatočne vysokej protilátkovej odpovede, je potřebné ich injikovať viackrát opakované v róznych dávkách a časových intervaloch. Sérum takto imunizovaných zvierat slúži ako zdroj protilátok najmS pri diagnostickom vyšetřovaní ohovov hydiny. Zmienený postup imunizácie má niekolko nevýhod. Získává sa heterogénna zmes protilátok, ktorých rozloženie sa v organizme producenta mění, je velmi róznorodé, kvalitativně a kvantitativné kolíše od jedného odběru po druhý a je neopakovatelné. Okrem toho sérum obsahuje nežiadúoe protilátky proti povrchovým antigénom, ktoré sa vyskytujú aj na normálnych buňkách. V dósledku toho je potřebné séra upravovat zložitými postupmi vysýtenia, aby sérum obsahovalo protilátky len proti povrchovým antigénom lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnýoh slezinových buniek hydiny.To date, antibodies to the lymphoblastoid cell line MSB1, which carries the diagnostic MATSA antigen on its surface, have been prepared by administering live MSB1 cells to test animals (rabbit, sheep). Since a single dose of cells is not sufficient to elicit a sufficiently high antibody response, they need to be injected multiple times at different doses and time intervals. The serum of the animals immunized in this way serves as a source of antibodies, in particular to the diagnostic examination of poultry. This immunization procedure has several drawbacks. A heterogeneous mixture of antibodies is obtained, the distribution of which varies in the producer organism, is very heterogeneous, qualitatively and quantitatively varies from one collection to the next and is unique. In addition, serum contains undesirable antibodies against surface antigens, which also occur on normal cells. As a result, sera need to be sophisticated by sophisticated saturation procedures so that the serum only contains antibodies against the surface antigens of the lymphoblastoid cell line designated MSB1 and normal spleen cells of poultry.
Touto úpravou dochádza k velkým stratám na sére a výraznému zníženiu titra Specifických protilátok. Pochopitelné proces vysýtenia nie je možné Standardizovat, v důsledku čoho sa i tak vysoká heterogenita konvenčnýoh sér ešte prehlbi. Okrem toho využitelnost takto připraveného diagnostického séra je znížená aj tým, že jeho Specifické polyklonálne protilátky sú z hladiska interakcie s povrchovými buňkovými antigénmi velmi různorodé. Naviac příprava dostatočného množstva lymfoblastoidných buniek MSB1 pre imunizačné účely je náročná na technické vybavenie pracoviska, kvalifikovaný personál a finančně prostriedky.This treatment results in large serum losses and a significant decrease in the specific antibody titer. Understandably, the saturation process cannot be standardized, as a result of which the high heterogeneity of conventional sera is even deepened. In addition, the usefulness of the diagnostic serum thus prepared is reduced by the fact that its specific polyclonal antibodies are very diverse in terms of their interaction with surface cell antigens. In addition, the preparation of sufficient quantities of MSB1 lymphoblastoid cells for immunization is demanding in terms of equipment, skilled personnel and financial resources.
Hybridom MSB-NTP-3 bol připravený známým spósobom, klonováním skupiny hybridómov v mSkkom agare, vzniklých fúziou buniek myšej 2-amino-6-hydroxy-8-azapurín /8-azaguanín/ rezistentnej myelómovej linie označenej NSO a slezinových buniek inbrednej linie myší BALB/c, imunizovaných lymfoblastoidnou buňkovou líniou MSB1 /G. Kóhler, C. Milstein,The MSB-NTP-3 hybridoma was prepared according to a known method by cloning a group of hybridomas in soft agar resulting from the fusion of mouse 2-amino-6-hydroxy-8-azapurine / 8-azaguanine / NSO-resistant myeloma line cells and BALB mouse inbred line spleen cells. / c, immunized with the lymphoblastoid cell line MSB1 / G. Kohler, C. Milstein,
G. W. Butcher, J. C. Howard: Nátuře 286, 550 /1977//.Butcher, G.W., Howard, J.C., Nature 286, 550 (1977) //.
Uvedené nevýhody v podstatnej miere odstraňuje vynález, ktorého podstata spočívá v myšom lymfocytárnom hybridóme MSB-NTP-3, produkujúcom monoklonálnu protilátku rozpoznávajúcu povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych slezinových buniek, podtriedy IgGl, kappa. Tento hybridom je uložený vo Virologiftkom ústave SAV, Mlýnská dolina 1, 817 03 Bratislava.These disadvantages are substantially eliminated by the invention, which is based on the murine lymphocyte hybridoma MSB-NTP-3, producing a monoclonal antibody recognizing the surface antigens of the lymphoblastoid cell line designated by the abbreviation MSB1 and normal spleen cells, subclass IgG1, kappa. This hybrid is deposited in the Virologift Institute of the SAS, Mlýnská dolina 1, 817 03 Bratislava.
Výhodou hybridómu je že produkuje izotypovo homogénnu protilátku, tzv. monoklonálnu protilátku, ktorá rozpoznává povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou M3B1 a normálnych slezinových buniek hydiny. Jednobunkový lymfocytárny hybridom MSB-NTP-3 rastie in vivo v peritoneálnej dutině BALB/c myší za súčasnej tvorby ascites.The advantage of the hybridoma is that it produces an isotype-homogeneous antibody, the so-called " a monoclonal antibody that recognizes the surface antigens of the lymphoblastoid cell line designated M3B1 and normal spleen cells of poultry. The single cell lymphocyte hybridoma MSB-NTP-3 grows in vivo in the peritoneal cavity of BALB / c mice while producing ascites.
Rastie aj in vitro v kultivačných médiách vhodných pre živočišné buňky. Taktiež po zmrazení a uložení v tekutom dusíku a opStovnom rozmražení si zachovává svoju schopnost produkovat monoklonálnu protilátku rozpoznávajúcu povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych slezinových buniek hydiny. Neobsahuje na rozdiel od konvenčných antisér nevhodné, nešpecifické, balastné protilátky.It also grows in vitro in culture media suitable for animal cells. Also, after freezing and storage in liquid nitrogen and re-thawing, it retains its ability to produce a monoclonal antibody recognizing the surface antigens of the lymphoblastoid cell line designated by the abbreviation MSB1 and normal spleen cells of poultry. It does not contain, unlike conventional antisera, inappropriate, non-specific, ballast antibodies.
Příklad 1Example 1
Pre přípravu hybridnej bunkovej linie sa použije 2.10? buniek myšej 2-amino-6-hydroxy-8-azapurín /8-azaguanín/ rezistentnej myelómovej bunkovej linie, ktoré sa pomocou 1 ml pFor the preparation of the hybrid cell line, 2.10? mouse 2-amino-6-hydroxy-8-azapurine / 8-azaguanine / resistant myeloma cell line cells which are treated with 1 ml of p
% hmot. polyetylénglykolu spoja s 1.10 slezinových lymfoidných buniek myši imunizovanej% wt. polyethylene glycol was coupled to 1.10 spleen lymphoid cells of mice immunized
3.10 MSB1 lymfoblastoidných buniek. V priebehu 14 dní vyrastú pod selektívnym tlakom kyseliny3.10 MSB1 lymphoblastoid cells. Within 14 days they grow under selective acid pressure
4-amino-pteroylglutámovej /aminopterínu/ hybridně buňkové linie, ktoré produkujú monoklonálne protilátky rozpoznávajúo povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych - o-lnových buniek hydiny.4-amino-pteroylglutamic / aminopterin / hybrid cell lines that produce monoclonal antibodies recognize the surface antigens of the lymphoblastoid cell line designated by the abbreviation MSB1 and normal-ovine poultry cells.
259232 6 fí259232 6 ph
Tieto buňky sa potom klónujú tak, že sa zmieša 0,5 % hmot. agaru s 5.10 až 10.10 myších slezinových buniek v médiu RPMI 1 640, ktoré obsahuje 100 mg.ml“1 tetrahydrátu dusičnanu vápenatého, 2 000 mg.ml 1 D-glukózy, 100 mg.ml 1 heptahydrátu síranu horečnatého,These cells are then cloned by mixing 0.5 wt. agar with 5.10 to 10.10 mouse spleen cells in RPMI 1640 medium containing 100 mg.ml -1 calcium nitrate tetrahydrate, 2,000 mg.ml 1 D-glucose, 100 mg.ml 1 magnesium sulfate heptahydrate,
400 mg.ml 1 chloridu draselného, 1 512 mg.ml 1 hydrogenfosforečnanu sodného, 6 000 mg.ml-1 monohydrátu dihydrogenfosforečnanu sodného, 100 mg.ml-1 kyseliny 2-amino-5-guanidínovalérovej /arginínu/, 50 mg.ml 1 kyseliny 2-aminosukcinamovej /asparagínu/, 20 mg.ml-1 kyseliny 2-aminojantarovej /kyseliny asparágovej/, 50 mg.ml-1 kyseliny 3',3'-ditiobis/2-aminopropánovej/, /cystínu/, 20 mg.ml-1 kyseliny 2-aminoglutárovej /kyseliny glutamovej/,- 300 mg.ml-1 kyseliny 2-aminoglutarámovej /glutamínu/, 1 mg.ml”1 kyseliny 2-aminoglutaraminyl-2-merkaptopropionyl-aminooctovej /gjutationu tj. glutaminyl-cysteinyl-glycínu/, 10 mg.ml-1 kyseliny aminooctovej /glycínu/, 15 mg.ml”1 kyseliny α-amino-l-imidazol-propiónovej /histidfnu/, 50 mg.ml“1 kyseliny 2-amino-3-metylvalérovej /izoleucínu/, 50 mg.ml”1 kyseliny 2-amino-4-metylvalérovej /leucínu/, 40 mg.ml”1 kyseliny 2,6-diaminohexánovej /lyzínu/, 15 mg.ml-1 kyseliny 2-amino-4-/metyltio/maslovej /metionínu/, 15 mg.ml”1 kyseliny 2-amino-3-fenylpropiónovej /fenylalanínu/, 20 mg.ml”1 kyseliny 2-pyrolidínkarboxylovej /prolinu/, 30 mg.ml-1 kyseliny 2-amino-3-hydroxypropiónovej /serínu/, 20 mg.ml 1 kyseliny 2-amino-3-hydroxymaslovej /treonínu/j 5 mg.ml kyseliny 2-amino-3-/3-indolyl/propionovej /tryptofanu/, 20 mg.ml kyseliny 2-amino-3/4-hydroxyfenyl/-propiónovej /tyrozínu/, 20 mg.ml 1 kyseliny 2-amino-3-metylmaslovej /valfhu/, 0,2 mg.ml”1 kyseliny 5-/2-oxoimidazolidíno/4,5-c/tiol-2-yl/pentánovej /biotínu/,400 mg.ml 1 potassium chloride, 1 512 mg.ml 1 sodium hydrogen phosphate, 6 000 mg.ml -1 sodium dihydrogen phosphate monohydrate, 100 mg.ml -1 2-amino-5-guanidinovaleric acid (arginine), 50 mg.ml 1 2-Aminosuccinamic acid (asparagine), 20 mg.ml -1 of 2-aminosuccinic acid (aspartic acid), 50 mg.ml -1 of 3 ', 3'-dithiobis (2-aminopropanoic acid), (cystine), 20 mg ml -1 of 2-aminoglutaric acid (glutamic acid), 300 mg.ml -1 of 2-aminoglutaramic acid (glutamine), 1 mg.ml -1 of 2-aminoglutaraminyl-2-mercaptopropionyl aminoacetic acid (gjutation) i.e. glutaminyl-cysteinyl-glycine (10 mg.ml -1 aminoacetic acid / glycine), 15 mg.ml -1 α-amino-1-imidazole-propionic acid (histidine), 50 mg.ml -1 of 2-amino- 3-methylvaleric (isoleucine), 50 mg.ml -1 of 2-amino-4-methylvaleric acid (leucine), 40 mg.ml -1 of 2,6-diaminohexanoic acid (lysine), 15 mg.ml -1 of 2- amino-4- (methylthio) butyric (methionine), 15 mg.ml -1 of 2-amino-3-phenylpropionic acid (phenylalanine), 20 mg.ml -1 of 2-pyrrolidinecarboxylic acid (proline), 30 mg.ml -1 2-amino-3-hydroxypropionic / serine /, 20 mg.ml 1 of 2-amino-3-hydroxybutyric acid / threonine / j 5 mg.ml of 2-amino-3- / 3-indolyl / propionic acid / tryptophan /. 20 mg.ml of 2-amino-3- / 4-hydroxyphenyl / propionate / tyrosine / 20 mg.ml 1 of 2-amino-3-methylbutyric / valfhu / 0.2 mg.ml "1 of 5 / 2-oxoimidazolidino [4,5-c] thiol-2-yl (pentanoic) biotin],
0,005 mg.ml”1 kobalt<X/K-/5,6-dimetylbenzimidazolyl//-kobaltβ-kyanokobamid vitamínu Bj^/,0,005 mg.ml ” 1 cobalt <X / K- (5,6-dimethylbenzimidazolyl) - - cobalt β-cyanocobamide of vitamin Bj ^ /,
0,250 mg.ml-1 D-N-/2,4-dihydroxy-3,3-dimetylbutyryl/-p-2-aminopropionát vápenatý /pantotenát vápenatý/, 3 mg.ml”1 2-hydroxyetyltrimetylamóniumchlorid /cholinchlorid/, 1 mg.ml”1 kyseliny N-/2-amino-4-hydroxypteridín-6-ylmetyl/-p-aminobenzoovej /kyseliny listovéj/, 35 mg.ml”1 /1,2,3,5/4,6/cyklohexándexol/ /myoinozitolu/, 1 mg.ml”1 pyridin-3-karboxyamidu /nikotínamidu/, 1 mg.ml“1 kyseliny 4-aminobenzoovej /kyseliny p-aminobenzoovej/, 1 mg.ml 1 3-hydroxy-4,5-bis/hydroxymetyl/-2-metylpyridínchloridu /pyridoxínchloridu/, 0,2 mg.ml”1 7,8-dimetyl-10-/l'-D-ribityl/izoaloxazinu/riboflavínu/, 1 mg.ml”1 3-/4-amino-2-metyl-pyrimidyl-5-metyl/-5-/2-hydroxyetyl/-4-metyltiazolu /tiamínchloridu/, 2 ,000 mg.ml 1 hydrogenuhličitanu sodného doplnenom s 2 mmol kyseliny 2-aminoglutarámovej /glutamínu/, 5.10 mol 2-merkaptoetanolu,0.250 mg.ml -1 DN- (2,4-dihydroxy-3,3-dimethylbutyryl) -p-2-aminopropionate (calcium pantothenate), 3 mg.ml -1 1-hydroxyethyltrimethylammonium chloride (choline chloride), 1 mg.ml " 1 N- (2-amino-4-hydroxypteridin-6-ylmethyl) -p-aminobenzoic acid (folic acid), 35 mg.ml" 1 / 1,2,3,5 (4,6) cyclohexanedexole) / myoinositol (1 mg.ml -1 pyridine-3-carboxyamide (nicotinamide)), 1 mg.ml -1 4-aminobenzoic acid (p-aminobenzoic acid), 1 mg.ml 11 3-hydroxy-4,5-bis (hydroxymethyl) / 2-metylpyridínchloridu / pyridoxínchloridu / 0.2 mg.ml "1 7,8-dimethyl-10 / l-D-ribityl / izoaloxazinu / riboflavin /, 1 mg.ml" 1 3/4-amino -2-methyl-pyrimidyl-5-methyl (-5- (2-hydroxyethyl) -4-methylthiazole / thiamine chloride), 2000 mg.ml 1 sodium bicarbonate supplemented with 2 mmol of 2-aminoglutaramic acid (glutamine), 5.10 mol 2-mercaptoethanol,
100 pg.ml-1 0-B-L-2-deoxy-2-/metylamino/~glukopyranozyl-/l-2/-0-«-L-deoxy-3-C-formyllyxofuranozyl-/l-4/-l,3-deoxy-l,3-diguanidoscyloinozitsulfátu_/streptomycínsulfátu/, 100 jednotiek na mililiter kyseliny 6-/N-fenylacetoamido/-penicilánovej /penicilínu G/, 1 mmol kyseliny N-2-hydroxyetylpiperazín-N'-2-etán sulfonovej /Hepesu/ sa rozpustí v trikrát redestilovanej vodě a doplní trikrát redestilovanou vodou na objem 900 ml roztoku, ktorý sa doplní 100 ml normálneho inaktivovaného koňského séra.100 -1 0 pg.ml-BL-2-deoxy-2 / methylamino / ~ glucopyranosyl / L-2 / -0 - «- L-deoxy-3-C-formyllyxofuranozyl- / L-4 / -l, 3-deoxy-1,3-diguanidoscyloinositsulfate (streptomycin sulfate), 100 units per milliliter of 6- (N-phenylacetoamido) -penicillanic acid (penicillin G), 1 mmol of N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid / Hepesu Dissolve in three times redistilled water and make up to three times with redistilled water to a volume of 900 ml of solution, which is supplemented with 100 ml of normal inactivated horse serum.
Výsledné pH takto připraveného kultivačného média je 7,2. Po zatuhnutí agaru sa na vrstvu 0,5 % hmot. agaru nanesie 100 hybridných buniek v 0,25 % hmot. agare. Po 10 dňoch vyrastú kolonie, ktoré sa pomnožia v médiu RPMI 1 640 doplnenom s 2 mmol kyseliny 2-amimoglutarámovej /glutamínu/, 5.10-^ mol 2-merkapto$tanolu, 100 jug.ml 1 0-K-L-2-deoxy~2-/metylamino/-glukopyranozyl-/1-2/-0-a-L-deoxy-3-C-formyllyxofuranozyl-/1-4/-1,3-deoxy-l,4-diguanidoscyloinozitSulfátu /streptomycínsulfátu/, 100 jednotiek na mililiter kyseliny 6-/N-fenylaceta~ miďo/-penicilánovej/ /penicilínu G/, 1 mmol kyseliny N-2-hydroxyetylpiperazín-N'-2-etán sulfonovej /Hepesi|/ sa rozpustí v trikrát redestilovanej vodě a doplní trikrát redestilovanou vodou na objem 900 ml roztoku, ktorý sa doplní 100 ml normálneho inaktivovaného koňského séra.The resulting pH of the culture medium thus prepared is 7.2. After the agar had solidified, 0.5 wt. agar plated 100 hybrid cells in 0.25 wt. agar. After 10 days colonies come up, which are propagated in RPMI 1640 supplemented with 2 mmol of 2-amimoglutarámovej / glutamine /, 5.10 - ^ mol of 2-mercapto $ butanol, 100 jug.ml 1 0-KL-2-deoxy ~ 2 - (methylamino) -glucopyranosyl- (1-2) -O-α-deoxy-3-C-formyllyxofuranosyl- (1-4) -1,3-deoxy-1,4-diguanidoscyloinosulfate (streptomycin sulfate), 100 units per milliliter 6- (N-phenylacetic-copper) -penicillanic acid () penicillin G), 1 mmol of N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (Hepesi) is dissolved in three times distilled water and made up to three times with distilled water to volume of 900 ml of solution to be supplemented with 100 ml of normal inactivated horse serum.
Výsledné pH takto připraveného kultivačného média je 7,2. V 1 ml kultivačného média sa nachádza 350 až 700 tisíc hybridómov MSB-NTP-3 produkujúcich 10 až 100 jug monoklonálnej IgGl, kappa, protilátky rozpoznávajucej povrchové antigény lymfoblastoidnej bunkovej linie označenej skratkou MSB1 a normálnych slezinových buniek.The resulting pH of the culture medium thus prepared is 7.2. 1 ml of culture medium contains 350 to 700 thousand MSB-NTP-3 hybridomas producing 10 to 100 µg of monoclonal IgG1, kappa, an antibody recognizing the surface antigens of the lymphoblastoid cell line designated MSB1 and normal spleen cells.
Příklad 2Example 2
Postupuje sa tak ako v příklade 1 s tým rozdielom, že sa v kultivačnom médiu použije nepredtestované běžné telacie fetálne sérum. Do takto připraveného kultivačného prostredia přenesené buňky po fúzii .nie sú schopné rást a produkovať monoklonálne protilátky.The procedure is as in Example 1 except that non-tested conventional calf fetal serum is used in the culture medium. The cells transferred to the culture medium thus prepared after the fusion are not able to grow and produce monoclonal antibodies.
Myší lymfocytárny hybridóm MSB-NTP-3 sa kultivuje pri teplote 37 °C. Stredný generačný čas je 19,4 hodin, modálny počet chromozómov je 24 mesiacov po fúzii 78 chromozómov. Produkovaná monoklonálna protilátka je myší imunoglobulln rozpoznávajúci povrchové antigény lymfoblastoidnej bundovéj linie označenej skratkou MSB1 a normálnych slezinových buniek hydiny, triedy IgGl, kappa.MSB-NTP-3 mouse lymphocyte hybridoma is cultured at 37 ° C. The mean generation time is 19.4 hours, the modal number of chromosomes is 24 months after the fusion of 78 chromosomes. The monoclonal antibody produced is a murine immunoglobulin recognizing the surface antigens of the lymphoblastoid jacket line designated by the abbreviation MSB1 and normal spleen cells of the poultry class IgG1, kappa.
Monoklonálna protilátka produkovaná myším lymfocytárnym hybridómom MSB-NTP-3-mÓže být použitá vo veterinárskej praxi pri vyšetřování a diferenciálnej diagnostike nádorových ochorení hydiny.The monoclonal antibody produced by the murine lymphocyte hybridoma MSB-NTP-3-MO can be used in veterinary practice in the examination and differential diagnosis of poultry cancer.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS861487A CS259232B1 (en) | 1986-03-04 | 1986-03-04 | Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS861487A CS259232B1 (en) | 1986-03-04 | 1986-03-04 | Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
CS148786A1 CS148786A1 (en) | 1988-02-15 |
CS259232B1 true CS259232B1 (en) | 1988-10-14 |
Family
ID=5349406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS861487A CS259232B1 (en) | 1986-03-04 | 1986-03-04 | Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS259232B1 (en) |
-
1986
- 1986-03-04 CS CS861487A patent/CS259232B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CS148786A1 (en) | 1988-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marshak-Rothstein et al. | Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus | |
US4350683A (en) | Antibody production from hybrid cell line | |
EP0232921A2 (en) | Monoclonal antibodies against hepatitis B virus | |
Coulie et al. | In vivo suppression of T‐dependent antibody responses by treatment with a monoclonal anti‐L3T4 antibody | |
Real et al. | Class 1 (unique) tumor antigens of human melanoma: identification of unique and common epitopes on a 90-kDa glycoprotein. | |
CA1225608A (en) | Monoclonal antibody to cardiac myosin heavy chain | |
FR2556739A1 (en) | CELL LINES SECRETING MONOCLONAL ANTIBODIES AGAINST PG E2, PREPARATION THEREOF, ANTIBODIES OBTAINED AND THEIR APPLICATION | |
CS259232B1 (en) | Mouse lymphocyte hybridom producing monoclonal antibody against poultry lymphocytes' surface antigens | |
CS259233B1 (en) | Mouse lymphocyte hybridom producing monoclonal antibody against msb1 lymphoblastoidal cellular line | |
CS261508B1 (en) | Mouse lymphocytar hybridom producing monoclal antitoxin against specific tumour antigen of cellular line msb1 | |
CS259231B1 (en) | Mouse lymphocyte hybridom producing monoclonal antibody inhibiting newcastle disease virus haemagglutination activity | |
Schultz et al. | Production and characterization of monoclonal antibody against infectious hematopoietic necrosis virus | |
CS259230B1 (en) | Mouse lymphocyte hybridom producing monoclonal antibodies against newcastle disease virus | |
EP0581108A2 (en) | Bispecific antibody reactive with sialyl-Lea antigen and CD3 | |
CA1235078A (en) | Monoclonal antibodies, to bovine serum albumin and their use in bsa isolation | |
CS260264B1 (en) | Mouse lymphocytar hybridome producing monocline antitoxins neutralizing virus of newcastle disease | |
Mahony et al. | A monoclonal antiidiotypic antibody to MOPC 315 IgA inhibits the growth of MOPC 315 myeloma cells in vitro. | |
EP0428485A1 (en) | Novel antiidiotypic monoclonal antibodies | |
Motté et al. | Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung | |
Wood | Monoclonal Antibodies | |
EP0535084A1 (en) | Improved ascites production of monoclonal antibodies using an immunosuppressive anti-cd4-related antibody | |
Rankin | The Production, Characterization and Therapeutic Use of Monoclonal Antibodies Directed Against the Idiotype of Human B Cell Non-Hodgkin Lymphomas | |
CS275658B6 (en) | MURINE LYMPHOCYTE HYBRIDOMA Bra FB6/a | |
BE895670A (en) | Producing several mono:clonal antibodies - from a single cell fusion, against leukaemia antigen | |
CS276203B6 (en) | Mouse hybridoma ifna2-n10 producing monoclonal antibody binding the human interferon alpha 2 |